Portal de Periódicos da CAPES

An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of N -{(1 S )-1-(3-Fluorophenyl)-3-[(3- endo )-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1 H -imidazo[4,5- c ]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)

2010; American Chemical Society; Volume: 54; Issue: 1 Linguagem: Inglês

10.1021/jm100978n

1520-4804

Paul A. Stupple, David V. Batchelor, Martin Corless, Patrick Dorr, David A. Ellis, David R. Fenwick, Sébastien R. G. Galan, R. Jones, Helen J. Mason, Donald S. Middleton, Manos Perros, Francesca Perruccio, Michelle Y. Platts, David C. Pryde, Débora F. Rodrigues, Nicholas N. Smith, Peter T. Stephenson, Robert O. Webster, Mike Westby, Anthony Wood,

Immune Cell Function and Interaction

Preventing entry of HIV into human host cells has emerged as an attractive approach to controlling viral replication. Maraviroc 1 is an approved antagonist of the human CCR5 receptor which prevents the entry of HIV. Herein, we report the design and discovery of a series of imidazopiperidine CCR5 antagonists which retain the attractive antiviral profile and window over hERG activity of maraviroc 1, combined with improved absorption profiles in rat and dog. Furthermore, this series of compounds has been shown to retain activity against a laboratory generated maraviroc-resistant HIV-1 strain, which indicates an alternative resistance profile to that of maraviroc 1. Compound 41f (PF-232798) was selected as a clinical candidate from the imidazopiperidine series and is currently in phase II clinical trials.